Skip to main content
. 2020 Feb 10;11:28. doi: 10.3389/fphar.2020.00028

Figure 1.

Figure 1

Comparison of different doses of CLI-095 and lipopolysaccharide (LPS) on H9C2 cardiomyocytes viability using CCK-8 assay. (A) Statistical analysis on cardiomyocytes viability using different doses of CLI-095. (B) Statistical analysis graph showing cardiomyocytes viability using different doses of LPS. #indicates a significant difference compared with myocardial ischemia-reperfusion injury (MIRI) group, P < 0.05.